One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei
Key facts
- Who runs it
- Beijing Tsinghua Chang Gung Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 132 people, planned
- Started
- 1 Nov 2025
- Expected to end
- 1 Nov 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- One HIPEC session
- Three HIPEC sessions
- Record updated
- 9 January 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Voluntarily consent to participate, sign informed consent, and be willing and able to comply with the study protocol
- Age 18-70 years
- Undergo CRS+HIPEC with pathological diagnosis of PMP of high grade with signet-ring cells, high grade, or low grade
- Karnofsky performance status (KPS) >60
- Adequate function of major organs as follows:; Hematology: WBC ≥3.5×10\^9/L, ANC ≥1.0×10\^9/L, LC ≥0.5×10\^9/L, PLT ≥80×10\^9/L, Hb ≥90 g/L; Hepatic function: AST, ALT, and TBIL ≤2×upper limit of normal (ULN); Renal function: serum creatinine <1.2×ULN; Coagulation: APTT ≤1.5×ULN; INR or PT ≤1.5×ULN; Cardiopulmonary function sufficient to tolerate major surgery and HIPEC; (5) Radiological Peritoneal Cancer Index (PCI) ≥15; (6) No local or systemic antitumor therapy within 1 month prior to CRS+HIPEC; (7) Adverse reactions from prior treatments have resolved before study initiation or, in the investigator's judgment, will not interfere with this study
Who cannot take part
- Concomitant hematological disorders or other malignancies
- Acute or subacute infectious disease
- History of allergy to cisplatin or docetaxel, or marked allergic diathesis or severe allergy history
- Psychiatric or psychological disorders preventing cooperation with treatment and efficacy evaluation
- Any other condition deemed unsuitable for enrollment by the investigator
- AST, ALT, or TBIL ≥2×ULN
- Serum creatinine ≥1.2×ULN
- Metastases to lung, brain, bone, or liver
- Severe mesenteric contraction
- Major organ dysfunction that cannot support the planned procedures
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Pseudomyxoma peritonei
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to compare the efficacy and safety of one versus three sessions of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) for patients with pseudomyxoma peritonei (PMP).
Read full original descriptionShow less
The main questions it aims to answer are:
* Does receiving three HIPEC sessions lead to better Progression-Free Survival (PFS) and Overall Survival (OS) compared to one session? * What are the differences in postoperative complications (e.g., infection, bowel obstruction, myelosuppression) and organ toxicity (e.g., liver/kidney injury) between the two regimens? * How do the different treatment schedules impact patients' quality of life?
Researchers will compare the experimental group (3 HIPEC sessions) to the control group (1 HIPEC session) to investigate the efficacy and safety of the additional sessions.
Participants will:
* Be randomly assigned to one of two groups:
1. Control Group: Receive only a single intraoperative HIPEC session following CRS. 2. Experimental Group: Receive two additional HIPEC sessions after CRS+HIPEC (on post-operative day 2 and day 4) at reduced drug doses. * Undergo scheduled safety checks for side effects on days 1, 3, 5, 7, and 10 post-HIPEC. * Attend a follow-up visit at 1 month after CRS+HIPEC and, if eligible, receive 6 cycles of standard postoperative chemotherapy. * Attend regular long-term follow-up visits for several years, which will include physical examinations, blood tests (for tumor markers), CT scans, and quality-of-life questionnaires (EORTC QLQ-C30 version 3.0).
The 2 groups in the trial
- Experimental GroupTreatment being tested
Treatment: Three HIPEC sessions
- Control GroupExisting treatment, for comparison
Treatment: One HIPEC session
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of One vs Three Cycles of Hyperthermic Intraperitoneal Chemotherapy After Cytoreductive Surgery for Pseudomyxoma Peritonei: A Multicenter Randomized Controlled Study
- Criteria questions
- Built from NCT07328737, who can take part
- Record updated
- 9 January 2026